<DOC>
	<DOC>NCT00639392</DOC>
	<brief_summary>The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics.</brief_summary>
	<brief_title>Phase 1 Study of Zoledronic Acid in Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>18 years and older Male or female with sickle cell disease Pain related to sickle cell disease Patient history of health services utilization for acute SCDrelated pain Patient history of use of narcotic analgesics for pain control within the past 6 months Able to tolerate hydration with 500 mL D51/2 NS prior to Zoledronic Acid or placebo Calculated creatinine clearance less than 60 mL/min Current active dental problems Recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction,implants) History of cirrhosis or chronic symptomatic liver disease; acute liver disease History of aspirininduced asthma History of allergy to zoledronic acid or similar chemicalentities Pregnant or nursing No prior bisphosphonate use Receipt of an investigational drug within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Sickle cell disease</keyword>
</DOC>